Cell Proliferation Protein Expression Research Articles

Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection.

PurposeTo investigate urothelial cell proliferation, cytoskeleton, inflammation, and barrier function protein expressions in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) after intravesical platelet-rich plasma (PRP) injectionsMethodsA total of 19 patients with IC/BPS underwent 4 monthly intravesical PRP injections. Bladder biopsies were taken at the first and fourth PRP treatment. The bladder specimens were analyzed using the Western blot and immunochemical staining for progenitor cell markers for sonic hedgehog (Shh), CD34, and cytoskeleton proteins cytokeratin 5 (CK5), CK14, CK20; barrier function markers for zonula occludens-1 (ZO-1), E-cadherin, and intercellular adhesive molecule-1, tryptase and transforming growth factor-β (TGF-β). Global response assessment (GRA) was used to evaluate treatment outcomes.ResultsThe mean age of patients was 55.6 years. After PRP injections, the functional bladder capacity and maximum flow rate increased, and the visual analogue scale (VAS) of pain, interstitial cystitis (IC) symptom index, IC problem index, O’Leary-Sant symptom score, and GRA improved in all patients. Urothelium Shh, CK5, ZO-1, E-cadherin, and TGF-β expressions increased significantly after repeated PRP injections. By subgrouping, according to PRP treatment outcomes, significant increases in Shh, E-cadherin, and ZO-1 expressions were noted only in patients with GRA ≥1 or improved VAS, but not in patients with GRA=0 and no improvement in VAS.ConclusionsThe level of urothelial barrier function protein and cell proliferation protein expression in the patients with IC/BPS was increased after repeat intravesical PRP injections. Intravesical repeat PRP injections may have potential to improve urothelial health and result in symptoms improvement in the patients with IC/BPS.

MP77-08 THE DEFICITS OF UROTHELIAL CYTOSKELETON AND CELL PROLIFERATION PROTEIN IN WOMEN WITH RECURRENT BACTERIAL CYSTITIS

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Kidney & Bladder II (MP77)1 Apr 2020MP77-08 THE DEFICITS OF UROTHELIAL CYTOSKELETON AND CELL PROLIFERATION PROTEIN IN WOMEN WITH RECURRENT BACTERIAL CYSTITIS Jia-Fong Jhang* and Hann-Chorng Kuo Jia-Fong Jhang*Jia-Fong Jhang* More articles by this author and Hann-Chorng KuoHann-Chorng Kuo More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000963.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recurrent urinary tract infection (rUTI) is a common disease in women, but its pathogenesis is still unclear. The aim of this study is to investigate urothelial cytoskeleton and cell proliferation protein expression in patients with rUTI. METHODS: Female patients with rUTI (symptomatic UTI > 3 times in recent one year) were recruited. One month after recovery from rUTI (absence of white blood cell in urinary analysis), the patients were asked to provide bladder specimens by cold-cup endoscopic biopsy. Patients with stress urinary incontinence were asked to provide bladder specimen as control. The specimens were investigated with western blot and immunochemical staining for urothelial cytoskeleton and cell proliferation protein, including sonic hedgehog (SHH), tumor protein 63 (TP63), cytokeratin 5 (CK5), CK14, CK20, zonula occludens (ZO)-1, E-cadherin and tryptase. GAPDH was used as normalizing protein for the quantification. RESULTS: A total of 16 rUTI and 8 control bladder specimens were analyzed. The cell proliferation protein SHH and TP63 expression were significantly lower in the rUTI urothelium than that in control (Figure 1). The cytoskeleton protein expression in the rUTI urothelium was also significantly lower than that in control bladders, including CK5, CK14 and CK20. The immunochemical staining showed CK5 and TP63 expression were mainly located near the basal layer of urothelium, while the CK20 expression was main located in the umbrella cells (Figure 2). The immunochemical staining results also showed decreased immunoactivity of CK5, CK14, CK20, TP63 and SHH in the patients with rUTI (Figure 2). CONCLUSIONS: Our results showed deficits of urothelium cell proliferation and cytoskeleton protein in the patients who had clinically recovered from rUTI. This finding indicates the urothelium function is still unhealthy even though clinical bladder inflammation had been subsided. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1166-e1166 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jia-Fong Jhang* More articles by this author Hann-Chorng Kuo More articles by this author Expand All Advertisement PDF downloadLoading ...